# Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy

Study · id `cardio:ct-nct01398592` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01398592](<https://clinicaltrials.gov/study/NCT01398592>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01398592

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.

## Technical summary

Registry record NCT01398592. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 187 participants (enrolled count; ClinicalTrials.gov record NCT01398592, source copy `cardio:ctgov-nct01398592-2013-02-12`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01398592, source copy `cardio:ctgov-nct01398592-2013-02-12`, retrieved 2026-10-26)
- Primary completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01398592, source copy `cardio:ctgov-nct01398592-2013-02-12`, retrieved 2026-10-26)
- Completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01398592, source copy `cardio:ctgov-nct01398592-2013-02-12`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT01398592, source copy `cardio:ctgov-nct01398592-2013-02-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01398592-2013-02-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
- Acronym: FPG-VISIT
- Condition: Diabetes Mellitus Type 2
- Intervention (Drug): Vildagliptin
- Intervention (Drug): Sitagliptin
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial (`cardio:pubmed-25457473`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9cf0600b2c3b60c584ad86509978f5ee0f9f444d06d3007f947e95dd51371b74
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
